• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SD filed by Charles River Laboratories International Inc.

    5/16/25 4:09:14 PM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $CRL alert in real time by email
    SD 1 dp228891_sd.htm FORM SD

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM SD

    Specialized Disclosure Report

     

    Charles River Laboratories International, Inc.

    (Exact name of registrant as specified in its charter)

     

    State of Delaware 001-15943 06-1397316
    (State or other jurisdiction (Commission (IRS Employer
    of incorporation or organization) File Number) Identification No.)
         

     

    251 Ballardvale Street  
    Wilmington, Massachusetts 01887
    (Address of principal executive offices) (Zip Code)

     

    Matthew Daniel, (781) 222-6000

    (Name and telephone number, including area code, of the person to contact in connection with this report.)

     

    Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:

     

    ☑Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2024.

     

    ☐Rule 13q-1 under the Securities Exchange Act (17 CFR 240.13q-1) for the fiscal year ended December 28, 2024.

     

     

     

    Introduction

     

    We are a leading, non-clinical global drug development partner with a mission to create healthier lives. For over 75 years, we have been in the business of providing the research models required in the research and development of new drugs, devices, and therapies. Over this time, we have built upon our original core competency of laboratory animal medicine and science (research model technologies) to develop a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, that supports our clients from target identification through non-clinical development. We also provide a suite of products and services to support our clients’ manufacturing activities. Utilizing our broad portfolio of products and services enables our clients to create a more efficient and flexible drug development model, which reduces their costs, enhances their productivity and effectiveness, and increases speed to market.

     

    Charles River is aware of the grave concerns and global issues that stem from the commercialization of Conflict Minerals in the Democratic Republic of the Congo and its adjoining countries. Thus, Charles River has been actively working with its business partners and others to promote responsible sourcing of Conflict Minerals within its supply chain.

     

    In accordance with Rule 13p-1 (17 CFR 240.13p-1) under the Securities Exchange Act of 1934, as amended, and Form SD (collectively, the Rule), Charles River has conducted a Reasonable Country of Origin Inquiry (RCOI) and related due diligence consistent with the Organization for Economic Co-operation and Development (OECD) Due Diligence Guidance for Responsible Supply Chains of Minerals from Conflict-Affected and High Risk Areas, and the OECD Supplement on Tin, Tantalum, and Tungsten (Second Edition, 2013) for its Endosafe Products (described below).

     

    For purposes hereof, all capitalized and italicized terms used herein and not otherwise defined shall have the meaning ascribed to such terms in the Rule.

     

    Caution Concerning Forward - Looking Statements

     

    This Current Report on Form SD includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate,” “believe,” “expect,” “will,” “would,” “may,” “estimate,” “plan,” “outlook,” and “project,” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements are based on the Company's current expectations and beliefs, and involve a number of risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from those stated or implied by the forward-looking statements. For example, we may use forward-looking statements when addressing topics such as: the steps we intend to take to mitigate the risk that our necessary Conflict Minerals may benefit armed groups; the implementation of satisfactory traceability and other compliance measures by our direct and indirect suppliers, on a timely basis or at all; whether smelters and refiners and other market participants responsibly source Conflict Minerals, and political and regulatory developments, whether in the Covered Countries, the United States or elsewhere. A further description of these risks, uncertainties, and other matters can be found in the Risk Factors detailed in the Company's Annual Report on Form 10-K as filed on February 19, 2025, as well as other filings the Company makes with the Securities and Exchange Commission. Because forward-looking statements involve risks and uncertainties, actual results and events may differ materially from results and events currently expected by the Company, and the Company assumes no obligation and expressly disclaims any duty to update information contained in this Form SD except as required by law.

     

     

     

    Product Overview

     

    Charles River does not knowingly or intentionally procure or otherwise source Conflict Minerals for any of its products that it manufactures or contracts to manufacture, except with regards to its Endosafe Products.

     

    Charles River’s Microbial Solutions business provides in vitro methods for conventional and rapid quality control testing. In connection therewith, the Microbial Solutions division contracts to manufacture for sale to third parties four (4) products (Endosafe®-nexgen PTS™ Model PTS150 and Model PTS150nw Portable Test Systems, Endosafe®-MCS™ Multi-Cartridge System, and Endosafe®-Nexus 200™ Automated Multi-Cartridge System; collectively the Endosafe Products) that contain electronic components, some of which include certain Conflict Minerals (tantalum, tin, tungsten and gold) that are necessary for their functionality and/or production.

     

    The Endosafe Products form a rapid, point-of-use test system comprised of test cartridges and use of a spectrophotometer where certain assays can be executed (e.g., Gram ID, Inhibition/Enhancement LAL, Glucan) and can determine if certain injectable therapeutics during the drug manufacturing and production processes are safe for human use (i.e., whether such therapeutics are endotoxin-free). Conflict minerals are common in manufacturing of electronic circuit boards and the components that are assembled to the circuit boards. For example, tantalum is used in certain capacitors within the power circuitry as it dramatically reduces the size of the capacitor and eliminates chemical disposal issues; and tin is used to solder electronics components on printed circuit boards consistent with industry practice due to its reliable performance.

     

    SECTION 1 - CONFLICT MINERALS DISCLOSURE

     

    Item 1.01 Conflict Minerals Disclosure and Report Reasonable Country of Origin Inquiry Efforts

     

    Charles River conducted, in good faith, a RCOI in accordance with the Rule, followed by related and reasonable due diligence in regards to its Endosafe Products and the Conflict Minerals utilized therein, which are necessary for their functionality and/or production. Our supply chain with respect to Endosafe Products is complex, as we purchase parts and materials directly, or contract with others to manufacture parts, from many suppliers; however, we do not purchase any Conflict Minerals directly from any smelters, mines or refiners. In most cases, there are multiple layers of third parties between Charles River and the ultimate upstream source of the Conflict Minerals.

     

    We engaged Assent Compliance Inc. (Assent) to help us obtain information, representations and certifications concerning the presence of Conflict Minerals in our Endosafe Products (if any), and the sourcing thereof.

     

    Specifically, we identified 85 suppliers who provide Endosafe Product components which may contain Conflict Minerals. With the help of Assent, we developed and executed a communication and inquiry program whereby each identified supplier was contacted a minimum of four times via phone-calls and email communications and asked to complete a Responsible Sourcing Initiative (RMI) Conflict Minerals Reporting Template (CMRT). The CMRTs and material correspondence from our suppliers were documented and aggregated into Assent’s survey platform, which can (among other functions) validate whether smelters and refineries used by suppliers are recognized as compliant with the RMI (formerly the Conflict Free Sourcing Initiative) protocol, and provide a risk assessment of the suppliers used. The following outputs were reported:

     

    •Response Rate: 94%, which represents the percentage of identified suppliers who responded to our inquiries regarding the presence of Conflict Minerals in our Endosafe Products, and the sourcing thereof.

     

    •The responding suppliers account for more than 95% of the components used in the Endosafe Products.

     

    •Of the 80 responding suppliers:

     

    •7 suppliers reported no Conflict Minerals are present in their components sold to Charles River;

     

    •23 suppliers reported Conflict Minerals are present in their components sold to Charles River, and such Conflict Minerals are not sourced from any Covered Country ;

     

    •30 suppliers reported Conflict Minerals are present in their components sold to Charles River, and such Conflict Minerals are sourced from a Covered Country, but such suppliers could otherwise represent they are not supporting armed groups since they buy Conflict Minerals exclusively from smelters and refiners that are CFSI compliant;

     

    •12 suppliers reported Conflict Minerals are present in their components sold to Charles River, and such Conflict Minerals are sourced from a Covered Country, but sourced from smelters or refiners not compliant with CFSI; and

     

    •25 suppliers could not provide sufficient detail as to whether they sourced from a Covered Country and/or whether smelters or refiners in their supply chain were CFSI compliant.

     

    Note: Suppliers sourcing more than one Conflict Mineral for components sold to Charles River may have responded differently with regards to each Conflict Mineral sourced, and therefore any such supplier may have been allocated to more than one output above.

     

     

     

    We are encouraged by the consistent engagement with our suppliers (75% suppliers representing responsible sourcing of Conflict Minerals, as compared with 57% in the 2023 report and 56% in the 2022 report). We credit this level of engagement to our internal and cross-functional Conflict Minerals Team (with members from Compliance, Legal, Procurement and Operations), which, with the help of Assent, actively engages with our suppliers and employees to explore solutions in sourcing Conflict Minerals responsibly, and raise awareness in our supply chain and among our employees of the issues and concerns surrounding Conflict Minerals.

     

    We have maintained our Conflict Minerals Law Statement (available at https://ir.criver.com/corporate-governance/highlights) which outlines our commitment to sourcing Conflict Minerals responsibly, and our Compliance & Ethics Hotline (available at 1-866-294-3699, or http://helpline.criver.com); and we have provided our suppliers and employees with access to Assent’s Conflict Mineral Resource Centers where tutorials, further education, and other resources can be found regarding Conflict Minerals and compliance related laws and regulations.

     

    Conclusion based on Reasonable Country of Origin Inquiry

     

    Despite our efforts to date, including our RCOI and related diligence, and in consideration of the complexity of our supply chain and the Endosafe Products themselves, we could not determine that our supply chain was not sourcing Conflict Minerals from one or more of the Covered Countries. While we believe a 94% response rate from our suppliers is significant, we understand further improvements to our evaluation efforts and diligence practices, as well as increased representations from our suppliers that Conflict Minerals are sourced responsibly, are needed to maintain, and advance this level of engagement with our suppliers and ultimately improve upon the areas where suppliers stated the source of the Conflict Minerals was either unknown or known to be non-conformant. These improvements over time will lead to a supply chain that is DRC Conflict Mineral Free; and therefore, we will continue to work with our partners, suppliers and supplier candidates to further develop our evaluation efforts and diligence practices.

     

    Public Conflicts Mineral Disclosure

     

    This information is publicly available at www.criver.com at the SEC filings link on the investor relations page.

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.

     

    CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

     

      /s/ Matthew Daniel
      Name: Matthew Daniel
      Title: Corporate Senior Vice President, General Counsel,
    Chief Compliance Officer & Corporate Secretary

     

    Date: May 16, 2025

     

    Form SD
    (Specialized Disclosure Report)

     

     

     

    Get the next $CRL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CRL

    DatePrice TargetRatingAnalyst
    5/14/2025$179.00Hold → Buy
    TD Cowen
    5/8/2025$170.00In-line → Outperform
    Evercore ISI
    3/21/2025$190.00 → $170.00Buy → Neutral
    Goldman
    3/4/2025$155.00 → $175.00Sell → Neutral
    Citigroup
    3/3/2025$188.00Sell → Neutral
    Redburn Atlantic
    1/22/2025Outperform → Mkt Perform
    William Blair
    1/17/2025$250.00 → $185.00Buy → Neutral
    UBS
    11/18/2024$164.00Hold → Underperform
    CLSA
    More analyst ratings

    $CRL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Charles River Laboratories to Present at Bank of America Health Care Conference

      Charles River Laboratories International, Inc. (NYSE:CRL) announced today that it will present at the Bank of America 2025 Health Care Conference on Wednesday, May 14th, at 8:40 a.m. PT (11:40 a.m. ET). Management will provide an overview of Charles River's strategic focus, business developments, and recent trends. A live webcast of the presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver.com. A webcast replay will be accessible through the same website after the presentation and will remain available for at least two weeks. About Charles River Charles River provides essential products and services t

      5/13/25 8:00:00 AM ET
      $CRL
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Charles River Laboratories Announces First-Quarter 2025 Results

      – First-Quarter Revenue of $984.2 Million – – First-Quarter GAAP Earnings per Share of $0.50 and Non-GAAP Earnings per Share of $2.34 – – Increases 2025 Guidance – – Repurchased $350 Million of Common Stock in First Quarter of 2025 – Charles River Laboratories International, Inc. (NYSE:CRL) today reported its results for the first quarter of 2025. For the quarter, revenue was $984.2 million, a decrease of 2.7% from $1,011.6 million in the first quarter of 2024. The impact of foreign currency translation reduced reported revenue by 0.9%. Excluding this impact, revenue decreased 1.8% on an organic basis driven by declines in all three business segments. In the first quarter of 2025, the

      5/7/25 7:01:00 AM ET
      $CRL
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Charles River Laboratories Announces Governance Updates and Strategic Review to Enhance Long-Term Stockholder Value

      – Board Approves Appointment of Four New Directors – – Strategic Planning and Capital Allocation Committee of the Board to Conduct Comprehensive Strategic Review of the Company's Business – – Enters into Cooperation Agreement with Elliott Investment Management – Charles River Laboratories International, Inc. (NYSE:CRL) today announced that four new directors will join its Board of Directors and that four long-time members of the Board will not seek re-election at the 2025 Annual Meeting of Shareholders. The Company also announced changes to its Board committees and a strategic review of the Company's business focused on enhancing long-term value for shareholders. Charles River's Board o

      5/7/25 7:00:00 AM ET
      $CRL
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $CRL
    Financials

    Live finance-specific insights

    See more
    • Charles River Laboratories Announces First-Quarter 2025 Results

      – First-Quarter Revenue of $984.2 Million – – First-Quarter GAAP Earnings per Share of $0.50 and Non-GAAP Earnings per Share of $2.34 – – Increases 2025 Guidance – – Repurchased $350 Million of Common Stock in First Quarter of 2025 – Charles River Laboratories International, Inc. (NYSE:CRL) today reported its results for the first quarter of 2025. For the quarter, revenue was $984.2 million, a decrease of 2.7% from $1,011.6 million in the first quarter of 2024. The impact of foreign currency translation reduced reported revenue by 0.9%. Excluding this impact, revenue decreased 1.8% on an organic basis driven by declines in all three business segments. In the first quarter of 2025, the

      5/7/25 7:01:00 AM ET
      $CRL
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Charles River Laboratories Schedules First-Quarter 2025 Earnings Release and Conference Call

      Charles River Laboratories International, Inc. (NYSE:CRL) will release first-quarter 2025 financial results on Wednesday, May 7th, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, May 7th, at 9:00 a.m. ET. Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website at ir.criver.com. A replay will be accessible through the same website. About Charles River Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate the

      4/15/25 4:30:00 PM ET
      $CRL
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Charles River Laboratories Announces Fourth-Quarter and Full-Year 2024 Results and Provides 2025 Guidance

      – Fourth-Quarter Revenue of $1.00 Billion and Full-Year Revenue of $4.05 Billion – – Fourth-Quarter GAAP Loss per Share of $(4.22) and Non-GAAP Earnings per Share of $2.66 – – Full-Year GAAP Earnings per Share of $0.20 and Non-GAAP Earnings per Share of $10.32 – – Provides 2025 Guidance – – Company Plans Stock Repurchases of Approximately $350 Million in 2025 – Charles River Laboratories International, Inc. (NYSE:CRL) today reported its results for the fourth quarter and full-year 2024 and provided guidance for 2025. For the quarter, revenue was $1.00 billion, a decrease of 1.1% from $1.01 billion in the fourth quarter of 2023. The impact of foreign currency translation reduced report

      2/19/25 7:00:00 AM ET
      $CRL
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $CRL
    Leadership Updates

    Live Leadership Updates

    See more
    • Charles River Laboratories Announces Governance Updates and Strategic Review to Enhance Long-Term Stockholder Value

      – Board Approves Appointment of Four New Directors – – Strategic Planning and Capital Allocation Committee of the Board to Conduct Comprehensive Strategic Review of the Company's Business – – Enters into Cooperation Agreement with Elliott Investment Management – Charles River Laboratories International, Inc. (NYSE:CRL) today announced that four new directors will join its Board of Directors and that four long-time members of the Board will not seek re-election at the 2025 Annual Meeting of Shareholders. The Company also announced changes to its Board committees and a strategic review of the Company's business focused on enhancing long-term value for shareholders. Charles River's Board o

      5/7/25 7:00:00 AM ET
      $CRL
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Charles River Laboratories and Autobahn Labs Announce Collaborative Program to Accelerate Academic Drug Discovery

      Agreement establishes Charles River as the preferred partner for Autobahn Labs, leveraging drug discovery and development capabilities to accelerate the translation of academic discoveries into novel therapeutics Under the agreement, Charles River will make an equity investment in Autobahn Labs Justin Bryans, Chief Scientific Officer, Discovery at Charles River, named to Autobahn's Board of Directors Charles River Laboratories International, Inc. (NYSE:CRL) and Autobahn Labs, a Samsara BioCapital-backed virtual accelerator for academic biotech, today announced a collaborative relationship that establishes Charles River as the preferred research partner to support Autobahn's grow

      7/24/24 8:00:00 AM ET
      $CRL
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Charles River Laboratories Adds Reshema Kemps-Polanco to Board of Directors

      Charles River Laboratories International, Inc. (NYSE:CRL) today announced the appointment of Reshema Kemps-Polanco, Executive Vice President and Chief Commercial Officer, Novartis US, to its Board of Directors. Ms. Kemps-Polanco has extensive pharmaceutical industry experience in leading commercial organizations that will provide a wealth of healthcare business leadership knowledge and sales and marketing expertise to Charles River's Board. As a member of the Board, Ms. Kemps-Polanco will serve on the Compensation and Strategic Planning and Capital Allocation Committees. "Reshema Kemp-Polanco's deep industry experience at two of the top-10, global pharmaceutical companies and demonstrated

      1/24/24 4:30:00 PM ET
      $CRL
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $CRL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chairman, President and CEO Foster James C bought $1,002,436 worth of shares (6,075 units at $165.01), increasing direct ownership by 3% to 183,639 units (SEC Form 4)

      4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)

      2/21/25 4:41:25 PM ET
      $CRL
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Corporate Executive VP & COO Girshick Birgit bought $249,250 worth of shares (1,514 units at $164.63), increasing direct ownership by 3% to 55,058 units (SEC Form 4)

      4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)

      2/21/25 4:38:37 PM ET
      $CRL
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Girshick Birgit gifted 350 shares and bought $248,298 worth of shares (1,322 units at $187.82), increasing direct ownership by 53% to 44,449 units (SEC Form 4)

      4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)

      11/21/23 5:07:01 PM ET
      $CRL
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $CRL
    SEC Filings

    See more
    • SEC Form SD filed by Charles River Laboratories International Inc.

      SD - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Filer)

      5/16/25 4:09:14 PM ET
      $CRL
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Charles River Laboratories International Inc.

      SCHEDULE 13G/A - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Subject)

      5/12/25 10:44:44 AM ET
      $CRL
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 10-Q filed by Charles River Laboratories International Inc.

      10-Q - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Filer)

      5/7/25 9:09:41 AM ET
      $CRL
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $CRL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Massaro George sold $19,260 worth of shares (140 units at $137.57), decreasing direct ownership by 2% to 5,575 units (SEC Form 4)

      4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)

      5/16/25 4:29:33 PM ET
      $CRL
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Director Massaro George sold $19,703 worth of shares (140 units at $140.73), decreasing direct ownership by 2% to 5,715 units (SEC Form 4)

      4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)

      5/15/25 4:41:58 PM ET
      $CRL
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • EVP, Corp Strategy & Develop Laplume Joseph W sold $72,705 worth of shares (500 units at $145.41), decreasing direct ownership by 2% to 19,513 units (SEC Form 4)

      4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)

      5/15/25 4:38:33 PM ET
      $CRL
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $CRL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Charles River upgraded by TD Cowen with a new price target

      TD Cowen upgraded Charles River from Hold to Buy and set a new price target of $179.00

      5/14/25 8:48:54 AM ET
      $CRL
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Charles River upgraded by Evercore ISI with a new price target

      Evercore ISI upgraded Charles River from In-line to Outperform and set a new price target of $170.00

      5/8/25 8:24:10 AM ET
      $CRL
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Charles River downgraded by Goldman with a new price target

      Goldman downgraded Charles River from Buy to Neutral and set a new price target of $170.00 from $190.00 previously

      3/21/25 8:03:14 AM ET
      $CRL
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $CRL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Charles River Laboratories International Inc.

      SC 13G - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Subject)

      11/8/24 10:52:38 AM ET
      $CRL
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Charles River Laboratories International Inc.

      SC 13G/A - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Subject)

      10/22/24 3:24:03 PM ET
      $CRL
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G/A filed by Charles River Laboratories International Inc. (Amendment)

      SC 13G/A - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Subject)

      2/13/24 5:01:02 PM ET
      $CRL
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care